CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

209637Orig1s000

OFFICER/EMPLOYEE LIST
DATE: December 5, 2017

TO: Administrative file for NDA 209637

FROM: Peter Franks, Regulatory Health Project Manager
Division of Metabolism and Endocrinology Products, Office of Drug Evaluation II

SUBJECT: Officer/Employee List for NDA 209637

APPLICATION/DRUG: NDA 209637, Ozempic, semaglutide, injection

The following officers or employees of FDA participated in the decision to approve this application and consented to be identified on this list:

Andraca-Carrera, Eugenio
Ball, Robert
Basso, Federica
Bearr, Elizabeth
Bi, Youwei
Cao, Christian
Chambers, Wiley A
Chen, Hepei
Chong, William
Dang, Qianyu
Dinatale, Miriam
Dorgan, Carolyn
Earp, Justin C
He, Jiwei
Hsueh, Ya-Hui (Catherine)
Hu, Yong
Khurana, Manoj
Kleppinger, Cynthia
Lalmansingh, Anika
Leginus, Joseph
Levenson, Mark
Liedtka, Jane
Lin, Karl K
Lungu, Andrecc
Manangeeswaran, Mohanraj
McGovern, Timothy
Mehra, Hina
Mollo, Sarah
Nguyen, Michael D.
Nguyen, Quynh Nhu
Olickal, Till
Qiang, Yandong
Ramaswamy, Muthukumar
Rimmel, Susan
Ryan, Debra
Sahajwalla, Chandrahana G
Smith, James P.
Stevens, Alan M
Thanh Hai, Mary
Tran, Suong T
Verhelyi, Daniela I
Wang, Yun
Wange, Ronald
Wickramaratne Senarath Yapa, Shalini
Williams, Marcia Britt
Williams, Sharon
Zander, Judith